Diligence memo · auto-generated · as of July 2, 2026
C2i Genomics, Inc.
C2i Genomics, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
C2i Genomics, Inc. operates in Biotechnology, based in NEW YORK.
Sub-sector tags: biotech.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
C2i Genomics, Inc. has raised $62M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $50M on 2021-03-31.
Most recent recorded round closed around 2021-03-31.
Valuation (modeled)modeled
Provath models C2i Genomics, Inc. at approximately $1.5B (range $155M–$3.7B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.79× the median modeled value of Series C Biotechnology companies in 2019–2021 (120 peers) — value vs value, same stage and era. Within the normal band (79% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 10 months.
Last raise 5.3 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 4.2× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 85% of Biotechnology peers (4293 compared).
Modeled value ranks above 93% of those peers.
Closest niche peers: Stem Biotech LLC, Kinnate Biopharma Inc., Arcutis Biotherapeutics, Inc., DNA Research INST LLC, M3 Biotechnology, Inc..
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.